This buildup of waste causes degeneration of the RPE cells in the central retina and results in progressive vision loss in both humans and mice with the mutation.
"To date, these mice provide one of the best models to study both Stargardt disease and a dry form of age-related macular degeneration. Using these mice, it is now possible to test a variety of treatment strategies including cell transplantation, gene therapy and pharmaceuticals," said Kang Zhang, M.D., Ph.D., assistant professor of ophthalmology and visual sciences at University of Utah's John A. Moran Eye Center and an investigator in the Program in Human Molecular Biology and Genetics at the University's Eccles Institute of Human Genetics.
Zhang predicts human clinical trials for treatments of the disease could be available in the next three to four years. "By engineering how much of the gene mutation is expressed in the eyes of a mouse, we can create many different ways of the disease presentation and therefore many points to intervene in the disease process," he said.
Patients with Stargardt disease typically begin showing symptoms of vision loss between the ages of 10 and 20. While Zhang doesn't expect new treatments to restore vision that has already been lost, he says it may be possible to stop further vision loss. Ultimately, he hopes to prevent vision loss before it occurs.
Age-related macular degeneration is the leading cause of blindness in Americans age 50 and older. There is currently no cure for the disease.
In addition to Zhang, the study included researchers from the University of Utah's Department of Neurobiology and Anatomy, the University of California at San Diego, the Retina Foundation of the Southwest in Dallas, and Brigham Young University.
The research was funded by the National Institutes of Health, Knights Templar Eye Research Foundation, the Ruth and Milton Steinbach Fund, Ronald McDonald House Charities, the Macular Vision Research Foundation, Research to Prevent Blindness, the Val and Edith Green Foundation, and the Simmons Foundation.